logo
L&T Q1 FY26 results: Profit grows 30% to ₹3,617 cr, surpasses estimates

L&T Q1 FY26 results: Profit grows 30% to ₹3,617 cr, surpasses estimates

Engineering and construction conglomerate Larsen & Toubro's (L&T's) profit (attributable to owners of the company) for the first quarter (Q1) of 2025-26 (FY26) grew by 29.8 per cent year-on-year (Y-o-Y) to ₹3,617.2 crore, amid higher revenues.
L&T's revenue from operations for Q1FY26 increased by 15.5 per cent Y-o-Y to ₹63,678.92 crore, amid healthy execution witnessed in its key projects and manufacturing portfolio.
The profit beat the Bloomberg analysts' poll estimate of ₹3,400.5 crore. The revenue also topped the analysts' estimate of ₹62,831.9 crore. L&T's other income during the quarter went up by 47 per cent to ₹1,357 crore on a Y-o-Y basis.
'Fifteen per cent revenue growth and a 30 per cent profit after tax growth augur well for the profitable execution of the various business contracts that the company has entered into,' said R Shankar Raman, whole-time director and chief financial officer, L&T.
The company's total expenses during the quarter grew by 15.2 per cent to ₹59,176.17 crore.
S N Subrahmanyan, chairperson and managing director, L&T, said, 'This quarter we have performed well across all financial parameters. Besides improved performance on all profit-and-loss parameters, the return ratios have also moved higher. The projects and manufacturing businesses of the company continue to perform well.'
L&T's consolidated order book stood at ₹6.12 trillion as of June 30, 2025, up 25 per cent Y-o-Y. The share of international orders remained at around 46 per cent.
The company received new orders worth ₹94,453 crore during the quarter, up 33 per cent Y-o-Y, the highest ever in a Q1. International orders stood at ₹48,675 crore, accounting for 52 per cent of the total order inflow.
The company's earnings before interest, tax, depreciation, and amortisation (Ebitda) for the quarter under review stood at ₹6,318 crore, up 12.52 per cent Y-o-Y. Meanwhile, its Ebitda margin stood at 9.9 per cent, compared to the margin of 10.2 per cent in Q1 of 2024-25.
The company's gross debt-to-equity ratio stood at 1.13x as of June 30, 2025, against the ratio of 1.12x as of June 30, 2024.
Referring to geopolitical tensions, tariff-related events, and technology disruptions, Raman said, 'To navigate through these headwinds and stay the course has been an exciting challenge for all of us in the company, and we are extremely pleased that we ended on the right side of the line.'
Global economic activity is expected to remain subdued with uneven momentum. Regional growth patterns have become more fragmented, as geopolitical and policy uncertainties reshape the economic outlook, L&T noted.
'Given the prevailing economic environment, the company remains focused on sustained execution of its large order book, scaling up the new businesses, and capitalising on the emerging opportunities,' the company added.
Sequentially, the company's revenue dipped by 14.4 per cent, while its profit declined by 34.2 per cent. L&T's shares listed on the BSE closed at ₹3,495.10 per equity share on Tuesday (29 July).
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bluspring Posts ₹777 Cr Revenue in Q1 FY26, Grows 13% YoY
Bluspring Posts ₹777 Cr Revenue in Q1 FY26, Grows 13% YoY

Fashion Value Chain

time9 minutes ago

  • Fashion Value Chain

Bluspring Posts ₹777 Cr Revenue in Q1 FY26, Grows 13% YoY

Bengaluru, India, August 1, 2025 – Bluspring Enterprises Limited [NSE: BLUSPRING, BSE: 544414], one of India's leading infrastructure management services firms, announced its financial performance for Q1 FY26 (ended June 30, 2025), reporting a 13% year-on-year revenue growth to ₹777 crore. While revenue showed strength, EBITDA stood at ₹24 crore, reflecting an 11% decline YoY, primarily due to seasonal softness in higher-margin segments like Telecom and Food Services. Adjusted Profit After Tax (PAT) came in at ₹13 crore, showing a 14% quarter-on-quarter increase despite a modest 5% YoY dip. Commenting on the results, Kamal Pal Hoda, Executive Director & CEO, Bluspring Enterprises, stated: 'We are pleased to report a steady start to FY26, with robust revenue of ₹777 crore and EBITDA of ₹24 crore (excluding investments), driven by disciplined execution and continued strength across our core businesses. While Facility & Food Services and Telecom & Industrial Services delivered double-digit Y-o-Y revenue growth on the back of healthy demand and strong execution, Security Services maintained a stable trajectory with 8% growth.' He further emphasized: 'Given the inherent seasonality in our high-margin businesses, particularly in the first quarter for Telecom and Food Services, we saw a decline in EBITDA margins. We also continued our investments in scaling foundit, as we remain confident in its potential to emerge as a profitable recruitment platform in the medium term.'

GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally
GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally

Business Standard

time40 minutes ago

  • Business Standard

GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to ₹279 crore for the June quarter. The drug firm had reported a net profit of ₹249 crore for the June quarter of the last fiscal. Total income declined marginally to ₹849 crore for the first quarter as compared with ₹850 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The company continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula, he added. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies, Akshikar noted. Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer. Shares of the company were trading 8.22 per cent down at ₹2,898.40 apiece on BSE. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Sensex crashes 600 points, investors lose  ₹6 lakh crore; what drove the Indian stock market down today?
Sensex crashes 600 points, investors lose  ₹6 lakh crore; what drove the Indian stock market down today?

Mint

timean hour ago

  • Mint

Sensex crashes 600 points, investors lose ₹6 lakh crore; what drove the Indian stock market down today?

The Indian stock market ended with significant losses on Friday, August 1, due to broad-based selling on the first day of the August derivatives series, amid concerns over tariffs, lacklustre earnings, and sustained foreign capital outflows. The Sensex ended 586 points, or 0.72 per cent, lower at 80,599.91, while the Nifty 50 settled at 24,565.35, down 203 points, or 0.82 per cent. The mid and small-cap segments suffered even deeper losses, as the BSE Midcap and Small-cap indices fell 1.37 per cent and 1.59 per cent, respectively. The sharp selloff eroded investors' wealth by ₹ 6 crore in a single session as the overall market capitalisation of BSE-listed firms dropped to ₹ 444 lakh crore from ₹ 450 lakh crore in the previous session. (This is a developing story. Please check back for fresh updates.)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store